placeholder
Importance
55
Trust
80
Urgency
30
REGULATORY · PRIMARY SOURCE
Nexus Health Solutions LLC dba Harper Meds - 728281 - 06/08/2026
The FDA warned Harper Meds, an online pharmacy, for making false claims about compounded semaglutide and tirzepatide drugs on its website. The agency said Harper Meds falsely claimed the drugs were FDA-approved and came from FDA-licensed facilities, which is illegal.
Analysis
FDA keeps cracking down on online pharmacies selling compounded semaglutide and tirzepatide with false labels. Less competition from bad actors helps Novo and Lilly sell their brand-name drugs.
- FDA issued warning letter MARCS-CMS 728281 to Harper Meds on June 8, 2026
- Harper Meds falsely claimed compounded semaglutide had 'Same active ingredient as Ozempic & Wegovy'
- Site falsely stated products came from 'FDA-licensed 503A Outsourcing Facilities' — no such designation exists
FDA Drug Approvals & Databases4d
Read